23rd Global Cardio Vascular Clinical Trialists (CVCT) Forum, 7-9 December 2026, Washington DC
Read more at this link
PH Update 2026 – Gateway to the 8th World Symposium, Sheraton Ann Arbor, Michigan, USA, October 2, 2026
The PH Update 2026 – Gateway to the 8th World Symposium will bring together experts in Pulmonary Hypertension for a day of scientific discussion, clinical updates and perspectives toward the 8th World Symposium on Pulmonary Hypertension. Click here for programme and to register
American Thoracic Society (ATS) annual conference 2026 discussions on AI, Innovation, and Humanism in medicine, American Medical Journal, July 1, 2026
The American Thoracic Society (ATS)’s annual international conference, held in Orlando in May 2026, drew over 14,000 participants from more than 100 countries for six days of scientific sessions, clinical trials, and educational programming. The overarching theme was a field in transition — one being reshaped by artificial intelligence and precision medicine, while holding firm
Efficacy and safety of sotatercept in patients with pulmonary arterial hypertension (PAH) associated with connective tissue disease (CTD), ATS international conference, May 18, 2026
New pooled data presented in the form of a scientific poster at the American Thoracic Society 2026 International Conference in Orlando suggests that sotatercept may significantly reduce morbidity and mortality risks in patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) — a particularly challenging population to treat. The analysis combined data from three phase
CardioMEMS-guided therapy shows promising results in pulmonary arterial hypertension: ARTISAN interim analysis presented at the American College of Cardiology Congress 2026, March 28–30
One of the most talked-about moments at this year’s American College of Cardiology Scientific Session was the presentation of the ARTISAN interim analysis by Dr. Raymond Benza — a study that was voted one of the Top 4 abstracts in Pulmonary Hypertension. ARTISAN (Afterload Reduction To Improve Right Ventricular Structure And FuNction), is a prospective, multicenter, open-label clinical
René Baumgart Foundation Research Prize 2026 – two awards for groundbreaking pulmonary hypertension research
At the 66th Congress of the German Society for Pneumology in Munich, the €5,000 René Baumgart Foundation research prize was awarded to two outstanding researchers working in the field of pulmonary hypertension (full text in German available at this link) English AI translation and summary Dr. Fenja Knöpp (Justus Liebig University, Giessen) was recognised for
The Alliance for Pulmonary Hypertension participates in the Annual Board Meeting of the European Reference Center for Rare Respiratory Diseases (ERN-LUNG), in Paris, March 23-24, 2026
On 23–24 March 2026, the Alliance for Pulmonary Hypertension attended the Annual Board meeting of ERN-LUNG, the European Reference Network for Rare Respiratory Diseases, in Paris. The Alliance was represented by Louise Bouman, Board member of the organisation and member of the ERN-LUNG E-PAG (European Patient Advisory Group). The meeting brought together healthcare professionals, researchers,
Louise Bouman, Board Member of the Alliance for Pulmonary Hypertension reporting from the PVRI Conference in Dublin, Ireland, 29 January-1st of February, 2026
Louise Bouman attended the Pulmonary Vascular Research Institute conference in Dublin on behalf of the Alliance for Pulmonary Hypertension, of which she is a Board Member. You can find her key highlights summary at this link and the full report below. Louise also attended a “Women in Pulmonary Hypertension” lunch, which you can read about
The Pulmonary Vascular Research Institute (PVRI) 2026 Congress is taking place in Dublin from 28 January-1 February 2026
The Pulmonary Vascular Research Institute (PVRI) Congress 2026 will take place in the historic city of Dublin from 28 January – 1 February 2026. ➡️ Explore the full Congress programme at this link The first and last day (28 January and 1 February) will be satellite meetings with the main plenary sessions happening 29-31 January.
Evolving paradigms in pulmonary hypertension: Highlights of the 6th French Pulmonary Hypertension Network Meeting, Respiratory Medicine and Research, Vol 88, November 2025
The 6th “Journées du Réseau Français de l’Hypertension Pulmonaire” (JRF-HTP), held in October 2024, provided a review of the evolving landscape in pulmonary hypertension (PH). The meeting brought together clinicians and researchers to exchange on the most recent scientific, clinical, and organizational advances in pulmonary hypertension. We are proud that a patient advocate was included as co-author,
Integrating Sotatercept Into Pulmonary Arterial Hypertension (PAH) Care: Vallerie McLaughlin, MD, American Heart Association, November 9, 2025
Vallerie McLaughlin, MD, the Kim A. Eagle M.D. Endowed Professor of Cardiovascular Medicine and Professor of Internal Medicine at the University of Michigan Medical School, presented the results of a pooled analysis of the PULSAR, STELLAR, and ZENITH trials of sotatercept in pulmonary arterial hypertension at the 2025 American Heart Association Scientific Sessions, held in
Pulmonary vascular diseases – State of the art session, European Respiratory Society Annual Congress 2025, Septermber 28, 2025
On Monday, 28 September 2025, a State of the Art Session was held at the European Respiratory Society (ERS) Annual Congress 2025 titled: “Pulmonary Hypertension associated with lung diseases: the most burning questions.” The session was chaired by Prof. Dr. Olivier Sitbon, Prof. Dr. David Montani, and Dr. Nesrin Ocal. Leading experts shared the latest
How it all started: The Aminorex Epidemic that Launched Systematic Primary Pulmonary Hypertension (PPH) Studies and the First Patient Registry
An article titled “The Genesis and Legacy of the NHLBI Patient Registry for the Characterization of Primary Pulmonary Hypertension”, published recently in Pulmonary Circulation, traces the historical development of primary pulmonary hypertension (PPH) research from its first pathological description by Ernest Romberg in 1891 through the establishment of the landmark US National Heart, Lung, and
What can ERN-LUNG offer for the future? Special session at the European Respiratory Society Annual Congress, Amsterdam, October 1, 2025 – 09:30–11:30 CEST
On Wednesday October 1, 2025, a special programme at the European Respiratory Congress will be discussing what can ERN-LUNG offer for the future. ERN-LUNG is a patient-centric network of European healthcare providers and patient organisations, committed Europe-wide and globally to reducing morbidity and mortality from rare lung diseases in people of all ages through: ✅
Important announcement: the date for the next World Symposium on Pulmonary Hypertension is now set!
Traditionally the World Pulmonary Hypertension Symposia series, started in Geneva in 1973 and held every 5 years after the Evian edition in 1998 (Venice 2003, Dana Point 2008, Nice 2013, Nice 2018), has marked the progresses in pulmonary hypertension science and has anticipated future developments. The published supplement including the symposia proceedings constitutes a collection
PVRI Drug Discovery Symposium, June 16-17: Key Insights, Louise Bouman, Chair of PHA Netherlands and Board Member of the Alliance for Pulmonary Hypertension
Louise Bouman, Chair of Stichting Pulmonale Hypertensie (PHA Netherlands) and Board Member of the Alliance for Pulmonary Hypertension is just back from Amsterdam where she attended the Pulmonary Vascular Institute (PVRI) Symposium on Drug Discovery and Development taking place on June 16-17. “I recently had the opportunity to attend an inspiring symposium organized by the
10-year Data on Oral Selexipag: Long-Term Survival, Safety, and Dosing Insights in Pulmonary Arterial Hypertension (PAH), oral session at ISHLT congress, April 29, 2025
Selexipag is an oral selective IP prostacyclin receptor agonist. This study, presented during an oral session at the International Society for Heart and Lung Transplant (ISHLT) congress on April 29, 2025, provides the longest follow-up data available for any pulmonary arterial hypertension therapy, tracking 574 patients originally randomized to selexipag in the GRIPHON trial, with
PVRI International Conference 2025 report, Navneet Singh, Katarina Zeder, Pulmonary Circulation, May 1, 2025
An editorial titled “PVRI International Conference 2025: Embracing Heterogeneity”, published in Pulmonary Circulation on May 1, 2025, summarizes the 2025 PVRI International Conference held in Rio de Janeiro, Brazil. The four-day gathering brought together experts from 25 countries across 5 continents to discuss advances in early diagnosis, risk stratification, and treatment approaches for various forms
“A wake-up call: key trends and policy asks for cardiovascular health in women”, European Parliament event, March 5, 2025
We were unfortunately unable to attend the European Parliament event which took place on March 5, 2025, but have read the minutes with great interest. Based on these we have put together some key takeaways as this topic is very relevant to pulmonary arterial hypertension patients, who are predominantly women. Opening Member of the European
Latest edition on “Mariposa” the quarterly magazine of the European PH organisation PHA Europe, is now out covering the annual conference, World PH Day and much more
In the Editor’s Note to “Mariposa” Hall Skaara, project manager at PHA Europe, highlights the organisation’s key 2024 achievements: Download the full issue of the magazine at this link on the PHA Europe website